Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation

Nicoletta Riva; Danielle E. Smith; Gregory Y. H. Lip; Deirdre A. Lane

首页> 外文期刊>Age and Ageing >Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation

【24h】

Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation

机译：年龄增长和出血风险是房颤抗凝处方的最强障碍

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Age and Ageing》 |2011年第6期|p.653-655|共3页
作者
Nicoletta Riva; Danielle E. Smith; Gregory Y. H. Lip; Deirdre A. Lane;
展开▼
作者单位

To whom correspondence should be addressed Tel: (+44) 121 507 5080;

Fax: (+44) 121 554 4083. Email:;

展开▼
收录信息美国《科学引文索引》(SCI);美国《化学文摘》(CA);
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-18 01:10:32

相似文献

外文文献
中文文献
专利

1. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. [J] . Riva N, Smith DE, Lip GY, Age and Ageing: The Journal of the British Geriatrics Society and the British Society for Research on Ageing . 2011,第6期

机译：年龄增长和出血风险是房颤抗凝处方的最强障碍。
2. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk [J] . Godino Cosmo, Melillo Francesco, Bellini Barbara, EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology . 2020,第17期

机译：经皮左心房阑尾闭合与非维生素K口服抗凝血剂在非瓣膜心房颤动的患者和高血汗风险
3. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors [J] . Chao Tze-Fan, Lip Gregory Y. H., Lin Yenn-Jiang, Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis . 2018,第4期

机译：口腔抗凝剂治疗心房颤动患者的入射危险因素和重大出血：基线的比较，随访和Delta具有较为可改性出血风险因素的方法
4. Self-management of Oral Anticoagulants by Patients with Atrial Fibrillation: How Effective and Safe Is It? [C] . R. Cazzin, P. Serra C. Lestuzzi International Workshop on Cardiac Arrhythmias . 2002

机译：心房颤动患者的口腔抗凝血剂自我管理：它有多效益和安全？
5. Switching from Vitamin K Antagonists to Non-vitamin K Oral Anticoagulants, Drug-Drug Interactions, and Health Outcomes among Working-Age Adults with Atrial Fibrillation [D] . Feng, Xue. 2018

机译：从维生素K拮抗剂切换到非维生素K口服抗凝剂，药物 - 药物相互作用，以及具有心房颤动的工作年龄成年人之间的健康状况
6. Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management [O] . Daniel TT Chong, Felicita Andreotti, Peter Verhamme, 2021

机译：亚洲心房颤动患者的直接口服抗凝剂：亚太地区心脏病学会的共识建议对血栓形成和出血风险管理的策略
7. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation [O] . N. Riva, D. E. Smith, G. Y. H. Lip, 2011

机译：推进年龄和出血风险是心房颤动中抗凝药处方最强的障碍

Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation

著录项

相似文献

相关主题

期刊订阅